These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 27668631)

  • 1. Current approaches to the management of diabetic macular edema.
    Hariprasad SM
    Am J Manag Care; 2016 Jul; 22(10 Suppl):s292-s299. PubMed ID: 27668631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management paradigms for diabetic macular edema.
    Mitchell P; Wong TY;
    Am J Ophthalmol; 2014 Mar; 157(3):505-13.e1-8. PubMed ID: 24269850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
    Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
    Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab for the management of diabetic macular edema.
    Stefanini FR; Arevalo JF; Maia M
    World J Diabetes; 2013 Apr; 4(2):19-26. PubMed ID: 23593532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal Therapy for Diabetic Macular Edema: An Update.
    Furino C; Boscia F; Reibaldi M; Alessio G
    J Ophthalmol; 2021; 2021():6654168. PubMed ID: 33688431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
    Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
    Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema.
    Sohn HJ; Han DH; Kim IT; Oh IK; Kim KH; Lee DY; Nam DH
    Am J Ophthalmol; 2011 Oct; 152(4):686-94. PubMed ID: 21782151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroids as part of combination treatment: the future for the management of macular edema?
    Bandello F; Battaglia Parodi M; Tremolada G; Lattanzio R; De Benedetto U; Iacono P
    Ophthalmologica; 2010; 224 Suppl 1():41-5. PubMed ID: 20714180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinal Vein Occlusion.
    Sawada O; Ohji M
    Dev Ophthalmol; 2016; 55():147-53. PubMed ID: 26501219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
    Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
    Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
    Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema: Report From RESTORE, RIDE, and RISE Trials.
    Bressler NM; Varma R; Mitchell P; Suñer IJ; Dolan C; Ward J; Ferreira A; Ehrlich JS; Turpcu A
    JAMA Ophthalmol; 2016 Feb; 134(2):160-6. PubMed ID: 26584450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical applications of cost analysis of diabetic macular edema treatments.
    Smiddy WE
    Ophthalmology; 2012 Dec; 119(12):2558-62. PubMed ID: 23062655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current trends in the pharmacotherapy of diabetic retinopathy.
    Kumar B; Gupta SK; Saxena R; Srivastava S
    J Postgrad Med; 2012; 58(2):132-9. PubMed ID: 22718058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.
    Do DV; Schmidt-Erfurth U; Gonzalez VH; Gordon CM; Tolentino M; Berliner AJ; Vitti R; Rückert R; Sandbrink R; Stein D; Yang K; Beckmann K; Heier JS
    Ophthalmology; 2011 Sep; 118(9):1819-26. PubMed ID: 21546089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Severity of diabetic macular edema (DME) in Seine St Denis among patients treated by anti-VEGF].
    Stéphan S; Fajnkuchen F; Addou-Regnard M; Grenet T; Nghiem-Buffet S; Chaine G; Giocanti-Auregan A
    J Fr Ophtalmol; 2014 Nov; 37(9):717-21. PubMed ID: 25308789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye.
    Bakbak B; Ozturk BT; Gonul S; Yilmaz M; Gedik S
    J Ocul Pharmacol Ther; 2013 Oct; 29(8):728-32. PubMed ID: 23848950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.